Completed
A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
Kidney Diseases
December 17, 2019
March 16, 2022
This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts.
Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension.
Participants in each cohort will be enrolled in a parallel assignment to one of two doses:
Phase2
Interventional
79
DRUG: DM199
March 16, 2022
DiaMedica Therapeutics Inc
Male & Female
18 years and older
A Clinical Trial is a research study in which people volunteer to help find answers to specific health questions. When carefully conducted, they are the safest and fastest way to find new treatments and ways to improve health.
REDUX was conducted for many reasons:
The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.